Recombinant human TIGIT Protein, Fc-Tag, 100µg

Background
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is also known as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane domain-containing protein 3 (VSTM3),which belongs to single-pass type I membrane protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.

Source
Recombinant Human TIGIT, Fc Tag (TIT-H5254) is expressed from human 293 cells (HEK293). It contains AA Met 22 - Pro 141 (Accession # Q495A1 -1).
Predicted N-terminus: Met 22

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 39.7 kDa. The protein migrates as 45-54 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity
Smith, Thurman, Zeng et al
Front Immunol (2023) 14, 1280986
(2) "Immune checkpoint inhibitors for multiple myeloma immunotherapy
Liu, Xu, Liu et al
Exp Hematol Oncol (2023) 12 (1), 99
(3) "TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
Tsakmaklis, Farowski, Zenner et al
BMC Cancer (2023) 23 (1), 1160
Showing 1-3 of 1382 papers.